Effectiveness of neoadjuvant chemotherapy in downstaging HER2+ and triple negative breast cancers.

No Thumbnail Available
Authors
Bennet, Jessica
Youssef, Magdi
Townend, Alice
Issue Date
2023
Type
Language
Keywords
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
Introduction: Neoadjuvant chemotherapy (NAC) is the administration of chemotherapy prior to surgical intervention, with the goal of downstaging of tumours to improve surgical outcomes or provide the option for breast conserving surgery where otherwise not possible. Triple negative breast cancer (TNBC), characterized by the lack of oestrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) and HER2+ cancers are known to respond well to NAC.
Description
Citation
Lagore, M., Bennet, J., Youssef, M. and Townend, A. (2023) Effectiveness of neoadjuvant chemotherapy in downstaging HER2+ and triple negative breast cancers. European Journal of Surgical Oncology; 49 (5) : e227.
Publisher
European Journal of Surgical Oncology
License
Journal
Volume
Issue
URI
https://hdl.handle.net/20.500.14445/965
PubMed ID
DOI
https://doi.org/10.1016/j.ejso.2023.03.042
ISSN
0748-7983
EISSN
Collections
Oncology and Cancer Care
Surgery